Polypeptide growth factors in gastroenteropancreatic neuroendocrine tumours

Endokrynologia Polska

Volumn 58, Issue 1, 2007, Pages 42-50

  Blicharz Dorniak, Jolanta ^a   Kos Kudla, Beata ^a,b   Kudla, Marek ^b   Foltyn, Wanda ^a   Marek, Bogdan ^b   Siemiñska, Lucyna ^b   Nowak, Mariusz ^b  

^a Division of Endocrinology   (Poland)

^b MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Epidermal growth factor; Fibroblast growth factor; Gastroenteropancreatic neuroendocrine tumours; Growth factors; Insulin like growth factor; Platelet derived growth factor; Vascular endothelial growth factor

Indexed keywords

EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR; NEUROPILIN 2; PLATELET DERIVED GROWTH FACTOR; SIGNAL PEPTIDE; SOMATOMEDIN C; TRANSFORMING GROWTH FACTOR ALPHA; VASCULOTROPIN A;

GASTROINTESTINAL TUMOR; HUMAN; METABOLISM; NEUROENDOCRINE TUMOR; PANCREAS TUMOR; REVIEW;

EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTORS; GASTROINTESTINAL NEOPLASMS; HUMANS; INSULIN-LIKE GROWTH FACTOR I; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; NEUROENDOCRINE TUMORS; NEUROPILIN-2; PANCREATIC NEOPLASMS; PLATELET-DERIVED GROWTH FACTOR; TRANSFORMING GROWTH FACTOR ALPHA; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 34548444250     PISSN: 0423104X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (75)

1. Cross M, Dexter TM. Growth factors in development, transformation and tumorigenesis. Cell 1991; 64: 271-280.
2. Kerbel S. Growth factors as mediators of malignant tumor progression. Cancer Metastasis Rev 1993; 12: 215-217.
3. Corleto VD, Delle Fave G, Jensen RT. Molecular insights into gastrointestinal neuroendocrine tumors: importance and recent advances. Dig Liver Dis 2002; 34: 668-680.
4. Zwick E, Bange J, Ullrich A. Receptor tyrosine kinase signalling as a target for cancer intervention strategies. Endocr Relat Cancer 2001; 8: 161-173.
5. Furstenberger G, Senn HJ. Insulin-like growth factors and cancer. Lancet Oncology 2002; 3: 298-302.
6. Toi M, Matsumoto T, Bando H. Vascular endothelial growth factor: its prognostic, predictive, and therapeutic implications. Lancet Oncology 2001; 2: 667-673.
7. Fraker DL, Jensen RT. Pancreatic endocrine tumors. In: DeVita VT, Hellman S, Rosenberg SA (eds). Cancer: Principles and Practice of Oncology. 5th ed. Philadelphia: Lippincott-Raven Publishers 1997: 1678-1704.
8. Jensen RT, Doherty GM. Carcinoid tumors and the carcinoid syndrome. In: DeVita VT, Hellman S, Rosenberg SA (eds). Cancer: Principles and Practice of Oncology. 6th ed. Philadelphia: Lippincott Williams & Wilkins 2001: 1813-1833.
9. Jensen RT. Natural history of digestive endocrine tumors. In: Mignon M, Colombel JF (eds). Recent Advances in Pathophysiology and Management of Inflammatory Bowel Diseases and Digestive Endocrine Tumors. Paris: John Libbey Eurotext 1999: 192-219.
10. Fraker DL, Jensen RT. Pancreatic endocrine tumors. In: DeVita V T, Hellman S, Rosenberg SA (eds). Cancer: Principles and Practice of Oncology, Ed. 5, Lippincott-Raven Publishing Company Philadelphia 1997: 1678.
11. Jensen RT, Gardner JD. Gastrinoma. In: Go VLW, DiMagno EP, Gardner JD, Lebenthal E, Reber HA, Scheele GA (eds). The Pancreas: Biology, Pathobiology and Disease. 2nd ed. Raven Press, New York 1993; 931-978.
12. Weber HC, Venzon DJ, Lin JT et al. Determinants of metastatic rate and survival in patients with Zollinger-Ellison syndrome: a prospective long-term study. Gastroenterology 1995; 108: 1637-1649.
13. Epstein RJ. Human Molecular Biology: an Introduction to the Molecular Basis of Health and Disease. Polish edition: Lewiñ- ski A, Liberski P.P. Biologia molekularna czowieka. Wydawnictwo Czelej Sp. z o. o. Wydanie I polskie, Lublin 2005; 11, 13: 279, 338-342.
14. Reinmuth N, Fan F, Liu W et al. Impact of insulin-like growth factor receptor-I function on angiogenesis, growth, and metastasis of colon cancer. Lab Invest 2002; 82: 1377-1389.
15. Lopez T, Hanahan D. Elevated levels of IGF-1 receptor convey invasive and metastatic capability in a mouse model of pancreatic islet tumorigenesis. Cancer Cell 2002; 1: 339-353.
16. Wulbrand U, Remmert G, Zofel P et al. mRNA expression patterns of insulin-like growth factor system components in human neuroendocrine tumours. Eur J Clin Invest 2000; 30: 729-739.
17. Hakam A, Yeatman TJ, Lu L et al. Expression of insulin-like growth factor-1 receptor in human colorectal cancer. Hum Pathol 1999; 30: 1128-1133.
18. Cardillo MR, Monti S, Di Dilverio F et al. Insulin-like growth factor (IGF)-I, IGF.II and IGF type I receptor (IGFR-I) expression in prostatic cancer. Anticancer Res 2003; 23: 3825-3836.
19. Maiorano E, Ciampolillo A, Viale G et al. Insulin-like growth factor 1 expression in thyroid tumors. Appl Immunohistochem Mol Morphol 2000; 8: 110-119.
20. Peters G, Gongoll S, Langner C et al. IGF-1R, IGF-1 and IGF-2 expression as potential prognostic and predictive markers in colorectal-cancer. Virchows Arch 2003; 443: 139-146.
21. Gydee H, O.Neill JT, Patel A et al. Differentiated thyroid carcinomas from children and adolescents express IGF-I and the IGF-I receptor (IGF-IR). Cancers with the most intense IGF.IR expression may be more aggressive. Pediatr Res 2004; 55: 709-716.
22. Nilsson O, Wangberg B, Theodorsson E et al. Presence of IGF-I in human midgut carcinoid tumours: an autocrine regulator of carcinoid tumour growth? Int J Cancer 1992; 51: 195-203.
23. Yu H, Rohan T. Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst 2000; 93: 1472-1489.
24. Ouban A, Muraca P, Yeatman T et al. Expression and distribution of insulin-like growth factor-1 receptor in human carcinomas. Hum Pathol 2003; 34: 803-808.
25. Wulbrand U, Wied M, Zofel P et al. Growth factor receptor expression in human gastroenteropancreatic neuroendocrine tumours. Eur J Clin Invest 1998; 28: 1038-1049.
26. Furukawa M, Raffeld M, Mateo C et al. Increased expression of insulin-like growth factor 1 and/or its receptor in gastrinomas is associated with low curability, increased growth, and development of metastases. Clinical Cancer Research 2005; 11: 3233-3242.
27. Van Gompel JJ, Chen H. Insulin-like growth factor 1 signaling in human gastrointestinal carcinoid tumor cells. Surgery 2004; 136: 1297-1302.
28. von Wichert G, Haeussler U, Greten FR et al. Regulation of cyclin D1 expression by autocrine IGF-1 in human BON neuroendocrine tumour cells. Oncogene 2005; 24: 1284-1289.
29. Höflich A, Yang Y, Huber S et al. Expression of IGFBP-2, -3 and -4 mRNA during differentiation of CaCo-2 colon epithelial cells. Am J Physiol 1996; 271: 922-931.
30. Boulle N, Logie A, Gicquel C et al. Increased levels of insulin-like growth factor II (IGF-II) and IGF-binding protein-2 are associated with malignancy in sporadic adrenocortical tumours. J Clin Endocrinol Metab 1998; 83: 1713-1720.
31. Menouny M, Binoux M, Babajko S. IGFBP-2 expression in a human cell line is associated with increased IGFBP-3 proteolysis, decreased IGFBP-1 expression and increased tumourigenicity. Int J Cancer 1998; 77: 874-879.
32. Von Wichert G, Jehle PM, Hoeflich A et al. Insulin-like growth factor-1 is an autocrine regulator of chromogranin A secretion and growth in human neuroendocrine tumor cells. Cancer Res. 2000; 60: 4573-4581.
33. Hansel DE, Rahman A, House M et al. Met proto-oncogene and insulin-like growth factor binding protein 3 overexpression correlates with metastatic ability in well-differentiated pancreatic endocrine neoplasms. Clinical Cancer Research 2004; 10: 6152-6158.
34. Ferry RJ, Jr, Cerri RW, Cohen P. Insulin-like growth factor binding proteins: new proteins, new functions. Horm Res 1999; 51: 53-67.
35. Furstenberger G, Senn HJ. Insulin-like growth factors and cancer. Lancet Oncol 2002; 3: 298-302.
36. Vadgama JV, Wu Y, Datta G et al. Plasma insulin-like growth factor 1 and serum IGF-binding protein 3 can be associated with the progression of breast cancer, and predict the risk of recurrence and the probability of survival in African-American and Hispanic women. Oncology 1999; 57: 330-340.
37. Goodwin PJ, Ennis M, Pritchard KI et al. Insulin-like growth factor binding proteins 1 and 3 and breast cancer outcomes. Breast Cancer Res Treat 2002; 74: 65-7-6.
38. Maitra A, Hansel DE, Argani P et al. Global expression analysis of well-differentiated pancreatic endocrine neoplasms using oligonucleotide microarrays. Clin Cancer Res 2003; 9: 5988-5996.
39. Ma PC, Maulik G, Christensen J et al. c-Met: structure, functions and potential for therapeutic inhibition. Cancer Metastasis Rev 2003; 22: 309-326.
40. Trusolino L, Comoglio PM. Scatter-factor and semaphorin receptors: cell signalling for invasive growth. Nat Rev Cancer 2002; 2: 289-300.
41. Zhang YW, Van de Woude GF. HGF/SF-met signaling in the control of branching morphogenesis and invasion. J Cell Biochem 2003; 88: 408-417.
42. Nilsson O, Wangberg B, Theodorsson E et al. Presence of IGF-1 in human midgut carcinoid tumours . an autocrine regulator of carcinoid tumor growth? Int J Cancer 1992; 51: 195-203.
43. Chasserot-Golaz S, Hubert P, Thierse D et al. Possible involvement of phosphatidylinositol 3-kinase in regulated exocytosis: studies in chromaffin cells with inhibitor LY 294002. J Neurochem1998; 70: 2347-235-6.
44. Nilsson O, Wangberg B, Kolby L et al. Expression of transforming growth factor alpha and its receptor in human neuroendocrine tumors. Int J Cancer 1995; 60: 645-651.
45. Krishnamurthy S, Dayal Y. Immunohistochemical expression of transforming growth factor alpha and epidermal growth factor receptor in gastrointestinal carcinoids. Am J Surg Pathol. 1997; 21: 327-333.
46. Horst Ibelgaufts. COPE Cytokines & Cells Online Pathfinder Encyclopaedia Version 16-9, 2006 (www.copewithcytokines.de).
47. Woodburn Jr. The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol. Ther 1999; 82: 241-250.
48. To CT, Tsao MS. The roles of hepatocyte growth factor/scatter factor and met receptor in human cancers. Oncol Rep 1998; 5: 1013-1024.
49. Maggiora P, Gambarotta G, Olivero M et al. Control of invasive growth by the HGF receptor family. J Cell Physiol 1991; 73: 183-18-6.
50. Di Renzo MF, Narsimhan RP, Olivero M et al. Expression of the Met/HGF receptor in normal and neoplastic human tissues. Oncogene 1991; 6: 1997-2003.
51. Modlin IM, Sandor A. An analysis of 8305 cases of carcinoid tumors. Cancer (Phila.) 1997; 79: 813-829.
52. Chen B-K, Ohtsuki Y, Furihata M et al. Co-overexpression of p53 protein and epidermal growth factor receptor in human papillary thyroid carcinomas correlated with lymph node metastasis, tumor size and clinicopathologic stage. Int J Oncol 1999; 15: 893-898.
53. Umeki K, Shiota G, Kawasaki H. Clinical significance of c-met oncogene alterations in human colorectal cancer. Oncology 1999; 56: 314-321.
54. Camp RL, Rimm EB, Rimm DL. Met expression is associated with poor outcome in patients with axillary lymph node negative breast carcinoma. Cancer (Phila.) 1999; 86: 2259-2266.
55. Chen BK, Ohtsuki Y, Furihata M et al. Overexpression of c-Met protein in human thyroid tumors correlated with lymph node metastasis and clinicopathologic stage. Pathol Res Pract 1999; 195: 427-433.
56. Cortesina G, Martone T, Galeazzi E et al. Staging of head and neck squamous cell carcinoma using the MET oncogene product as marker of tumor cells in lymph node metastases. Int. J. Cancer 2000; 89: 286-292.
57. Sawatsubashi M, Sasatomi E, Mizokami H et al. Expression of c-Met in laryngeal carcinoma. Virchows Arch 1998; 432: 331-336.
58. Di Renzo MF, Olivero M, Ferro S et al. Overexpression of the c-MET/HGF receptor gene in human thyroid carcinomas. Oncogene 1992; 7: 2549-2553.
59. Hirose Y, Kojima M, Sagoh M et al. Clinical importance of c-Met protein expression in high grade astrocytic tumors. Neurol Med Chir (Tokyo) 1998; 38: 851-858.
60. Peghini PL, Iwamoto M, Raffeld M et al. Overexpression of epidermal growth factor and hepatocyte growth factor receptors in a proportion of gastrinomas correlates with aggressive growth and lower curability. Clin Cancer Res 2002; 8 (7): 2273-86.
61. Papouchado B, Erickson LA, Rohlinger AL et al. Epidermal growth factor receptor and activated epidermal growth factor receptor expression in gastrointestinal carcinoids and pancreatic endocrine carcinomas. Mol Pathol 2005; 18: 1329-1336.
62. Chaudhry A, Funa K, Oberg K. Expression of growth factor peptides and their receptors in neuroendocrine tumors of the digestive system. Acta Oncol. 1993; 32: 107-114.
63. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress Endocr Rev 2004; 25: 581-611.
64. Hicklin DJ, Ellis LM. J Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. Clin Oncol 2005; 23: 1011-1027.
65. Gimbrone MA Jr, Leapman SB, Cotran RS et al. Tumor dormancy in vivo by prevention of neovascularization. J Exp Med 1972; 136: 261-27-6.
66. La Rosa S, Uccella S, Finzi G et al. Localization of vascular endothelial growth factor and its receptors in digestive endocrine tumors: correlation with microvessel density and clinicopathologic features. Hum Pathol 2003; 34: 18-27.
67. Terris B, Scoazec JY, Rubbia L et al. Expression of vascular endothelial growth factor in digestive neuroendocrine tumours. Histopathology. 1998; 32: 133-138.
68. Cohen T, Herzog Y, Brodzky A et al. Neuropilin-2 is a novel marker expressed in pancreatic islet cells and endocrine pancreatic tumours. J Pathol 2002; 198: 77-82.
69. La Rosa S, Uccella S, Erba S et al. Immunohistochemical detection of fibroblast growth factor receptors in normal endocrine cells and related tumors of the digestive system. Appl Immunohistochem Mol Morphol 2001; 9: 319-328.
70. Ramage J, Davies AHG, Ardill J et al. Guidelines for the management of gastroenteropacreatic neuroendocrine (including carcinoid) tumours. Gut 2005; 54: 1-1-6.
71. Laird AD, Vajkoczy P, Shawver LK. SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors. Cancer Res. 2000; 60: 4152-4160.
72. Traxler P, Allegrini PR, Brandt R. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity. Cancer Res. 2004; 64: 4931-4941.
73. Mendel DB, Laird AD, Xin X. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003; 9: 327-337.
74. Hopfner M, Baradari V, Huether A et al. The insulin-like growth factor receptor 1 is a promising target for novel treatment approaches in neuroendocrine gastrointestinal tumours. Endocr Relat Cancer 2006; 13: 135-149.
75. Nilsson O, Wangberg B, McRae A et al. Growth factors and carcinoid tumours. Acta Oncol 1993; 32: 115-12-4.